ATC Group: N05AC01 Periciazine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05AC01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N05 Psycholeptics
3 N05A Antipsychotics
4 N05AC Phenothiazines with piperidine structure
5 N05AC01 Periciazine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 50 mg
PAREN - Parenteral 20 mg

Active ingredients in N05AC01

Active Ingredient Description
Periciazine

Pericyazine is a neuroleptic with cardiovascular and antihistamine effects similar to those of chlorpromazine, but it has a stronger antiserotonin effect and a powerful central sedative effect.

Medicines in this ATC group

Australia (AU)

Brazil (BR)

Canada (CA)

Estonia (EE)

France (FR)

Hong Kong (HK)

Japan (JP)

Netherlands (NL)

New Zealand (NZ)

Spain (ES)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.